


1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re application of:
Richard Rosenbloom

Application No.
10/045,790

Filed: January 14, 2002

For: Oral compositions and Methods For
Prevention, Reduction And Treatment
Of Radiation Therapy

:
:
: Group Art Unit:
: 1617
:
: Examiner: S.A. Jiang, Ph.D
:
: Attorney Docket No.:
: QUIG-1006USCIP

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37
C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.56 and 1.97 and MPEP §2280, Applicant respectfully submits herewith information, which the Examiner is asked to consider. The documents submitted herewith are listed on the attached Substitute Form PTO 1449 (in duplicate). No fee is believed to be due in connection with this submission. However, if any fee is due; the Commissioner is authorized to charge Deposition Account No. 50-0462. Moreover, please credit any overpayment to Deposit Account No. 50-2462.

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Date:

April 6, 2004

I hereby certify that this paper, along with any document or paper referred to as being attached or enclosed, is being sent in a pre-paid envelope first class mail to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EDNA SCHMITTNGER
Name of person sending correspondence

Elena Schmittner
Signature of person sending correspondence

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Substitute PTO 1449 form.

This submission does not represent that a search has been made (37 C.F.R. §1.97(g)) or that no better art exists and does not constitute an admission that each or all of the listed documents are material (37 C.F.R. §1.97(h)) or constitute "prior art." The filing of this information disclosure statement shall not be construed as an admission against interest in any matter. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

If the Examiner applies any document as prior art against any claims in the application and Applicant determined that the cited document does not constitute "prior art" under United States law, Applicant reserves the right to present to the Patent Office the relevant facts and law regarding the appropriate status of such document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should one the document be applied against the claims of the present application.

Other Co-pending U.S. Patent Applications

The Quigley Corporation has the following other co-pending U.S. Patent applications which the applicant would like to call to the attention of the Examiner:

U.S. Patent application no. 10/369,025, filed on December 19, 2002.

U.S. Patent application no. 09/847,121, filed on May 2, 2001.

U.S. Patent application no. 10/288,825, filed on November 6, 2002.

U.S. Patent application no. 09/993,003, filed on November 6, 2001.

U.S. Patent application no. 10/132,642, filed on April 25, 2002.

U.S. Patent application no. 10/341,508, filed on January 13, 2003.

U.S. Patent application no. 10/288,761, filed on November 6, 2002.

U.S. Patent application no. 10/279,315, filed on October 24, 2002.


U.S. Patent application no. 10/359,889, filed on February 6, 2003.

U.S. Patent application no. 10/421,276, filed on April 23, 2003.

U.S. Patent application no. 10/128,382, filed on April 23, 2002.


Respectfully submitted,

Date: 4/6/2004



Kevin J. Dunleavy
Registration No. 32,024


KNOBLE YOSHIDA & DUNLEAVY, LLC
(Customer No. 21,302)
Eight Penn Center
Suite 1350
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103
Telephone: (215) 599-0600
Facsimile: (215) 599-0601



Examiner Initial	Item No.	Document No.	Date	Name	Class	Subclass
	1US	5,561,110	October 1, 1996	Michaelis, et al.		
	2US	5,866,578	February 2, 1999	Mylari, et al.		
	3US	4,210,667	July 1, 1980	Sarges, et al.		
	4US	5,550,249	August 27, 1996	Della Valle, et al		
	5US	5,665,360	September 9, 1997	Mann		
	6US	6,069,168	May 30, 2000	Horrobin, et al.		
	7US	4,232,040	November 4, 1980	Waterbury		
	8US	5,981,594	November 9, 1999	Okamoto, et al.		
	9US	5,958,379	September 28, 1999	Regenold, et al		
	10US	5,840,736	November 24, 1998	Zelle, et al		
	11US	4,147,795	April 3, 1979			
	12US	5,011,840	April 30, 1991	Sarges, et al.		
	13US	6,296,861	October 2, 2001	Perricone		
	14US	4,617,187	October 14, 1986	Okuyama, et al		
	15US	4,822,816	April 18, 1989	Markham		
	16US	5,070,085	Dec. 3, 1991	Markham		
	17US	5,614,224	Mar. 25, 1997	Womack		
	18US	5,976,579	Nov. 2, 1999	McLean		
	19US	5,883,086	Mar. 16, 1999	Craft		
	20US	5,804,168	Sep. 8, 1998	Murad		
	21US	5,595,982	Jan. 21, 1997	Harless		
	22US	6,299,896	Oct. 9, 2001	Cooper et al.		
	23US	5,824,666	October 1, 1998	Deckner et al.		
	24US	5,922,335	July 1, 1999	Ptchelintasev, Dimitri		
	25US	4,250,097	February 1, 1981	Pfister, Jurg R.		
	26US	6,555,573	April 1, 2003	Rosenbloom, Richard Allen		
	27US	4,627,973	December 1, 1986	Moran et al		
	28US	6,054,128A	April 1, 2000	Wakat, Diane		
	29US	6,051,602	April 1, 2000	Bissett, Donald Lynn		
	30US	5,686,082	November 1, 1997	N'Guyen, Quang-Lan		
	31US	5,648,083	July 1, 1997	Blieszner et al		
	32US	5,972,999	October 1, 1999	Murad, Howard		
	33US	5,709,868	January 1, 1998	Perricone, Nicholas V.		
	34US	5,872,140	February 1, 1999	Hesse et al.		
	35US	5,972,359	October 1, 1999	Sine et al.		
	36US	6,162,801	December 1, 2000	Kita		
	37US	6,048,886	April 1, 2000	Neigut		
	38US	5,876,737	March 1, 1999	Schonrock et al.		
	39US	5,952,391	September 1, 1999	Gers-Barlag et al.		
	40US	5,976,568	November 1, 1999	Riley		
	41US	5,770,260	July 1, 1998	Kim et al.		
	42US	6,592,896	July 15, 2003	Rosenbloom, Richard Allen		
	43US	6,596,313	July 22, 2003	Rosenbloom, Richard Allen		
	44US					
	45US					
	46US					
	47US					

EXAMINER:

DATE CONSIDERED:



Examiner Initial	Item No.	Foreign Patent Document No.	Date	Country	Translation (Yes/No)
	1F	WO 97/18817	May-97	Japan	Yes
	2F	JP 07324037A	December 1, 1995	Japan	Yes
	3F				
	4F				
	5F				
	6F				
	7F				
	8F				
	9F				
	10F				
	11F				
	12F				
	13F				
	14F				
	15F				
	16F				
	17F				
	18F				
	19F				
	20F				
	21F				
	22F				
	23F				
	24F				
	25F				
	26F				
	27F				
	28F				
	29F				
	30F				
	31F				
	32F				
	33F				
	34F				
	35F				
	36F				
	37F				
	38F				
	39F				
	40F				
	41F				
	42F				
	43F				
	44F				
	45F				
	46F				
	47F				

EXAMINER:

DATE CONSIDERED:

FORM PTO-1449 Modified

Filing Date: 1/14/2002


List of Patents and Publications Cited by Applicant

Group: 1617

U.S. Patent Trademark Office

Applicant: Rosenbloom


Docket No.: QUIG-1006USCIP



Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	1OD	Himmerich S., et al., "Effect of Vitamins E and C on Nitric Oxide Production in Oxidized Low Density Lipoprotein Treated Human Aortic Endothelial Cells", <u>Academic Press</u> ; 2000, internet download at http://www.academicpress.com/www/journal/niox/9204.html
	2OD	Asahi K, et al., "Nitric Oxide Inhibits the Formation of Advanced Glycation End Products", <u>Kidney Int</u> 2000 Oct;58(4):1780-7
	3OD	Van Acker et al., "Structural Aspects of Antioxidant Activity of Flavonoids", <u>Free Radic Biol Med</u> 1996;20(3):331-42
	4OD	Roche Vitamins for Cosmetics, pages 1 to 5, September 4, 1985.
	5OD	Natural Medicine Online, "Quercetin: A Review of Clinical Applications" by L. Stephen Coles M.D., Ph.D., pages 1 to 5.
	6OD	"Ultraviolet Irradiation Injury and Repair" by Bernard Idson, Ph.D., January 1992, pages 78 to 81.
	7OD	"Role of Nitric Oxide in Pain" by Jai Pal Singh, Doo Hyam Lee, Asavari Wagle and David Lodge, 2000 Academic Press.
	8OD	"The Neuronal NO synthase inhibitor 7-nitro-indazole facilitates the antinociception elicited by the electrical stimulation of the secondary somatosensory cortex in the rat" by Ryotaro Kuroda, Atsufumi Kawabata, Naoyuki Kawao, Wakana Umeda, Hiroko Yoshimura, 2000 Academic Press.
	9OD	"Over-the Counter Drug is Treatment for Alzheimer's" by Terri Mitchell and Amber Needham, <u>LE Magazine</u> , November 2000, page 1 to 9.
	10OD	"Ascorbate 6-palmitate protects human erythrocytes from oxidative damage", January 1999, PubMed.
	11OD	"Analgesic activity of certain flavone derivatives: a structure-activity study", January 1993, PubMed.
	12OD	Medscape Medline Abstract, "The hydroxyl free radical reactions of ascorbyl palmitate as measured in various in vitro models" by Perricone N, Nagy K, Horvath F, Dajko G, Uray I, Zs.-Nagy I, September 1999.
	13OD	Medscape Medline Abstract, "Making vitamin C lipophilic enhances its protective effect against free radical induced peroxidation of low density lipoprotein" by Liu ZQ, Ma LP, Liu ZL, September 1998.
	14OD	Medscape Medline Abstract, "Novel pharmacological activity of a vitamin (novel pharmacological action of vitamin D)", by Fukuoka M, Ohta T and Kiyoki M, October 1997.
	15OD	Medscape Medline Abstract, "A vitamin D(3) derivative (CB1093) induces nerve growth factor and presents neurotrophic deficits in streptozotocin-diabetic rats", by Riaz S, Malcangio M, Tomlinson DR, November 1999.
	16OD	Naturesrain, "Our Products work by returning you skin to it's natural state. Here's How... Restore Normal NaPCA levels"
	17OD	Quercetin, "Protect your Health With This Important Flavonoid", by Dr. David G. Williams, ImmuneSupport.com

EXAMINER:

DATE CONSIDERED:



Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	18OD	Roche, Certificate of Analysis for D-Panthenol, by C. Conduit, November 10, 1999.
	19OD	Roche, Certificate of Analysis for di-Alpha Tocopheryl Acetate, by Karen Moll, March 3, 2000.
	20OD	
	21OD	Roche, Certificate of Analysis for vitamin A Palmitate, by Dr. R. Schwetzler, May 2, 2000
	22OD	Roche, Certificate of Analysis for Ascorbyl Palmitate, by Dr. K. Deutschman, November 12, 1999
	23OD	Healthnotes, "Quercetin", pages 1-3,
	24OD	Henahan J., <u>Dermatology Times</u> , "New Aqueous Vitamin C blocks UV rays" 1991
	25OD	American Academy of Dermatology, "Eczema/Atopic Dermatitis", 1999, pages 1-4, retrieved October 15, 2002 @ http://www.aad.org/pamphlets/eczema.html
	26OD	Ponec M., et al., "The formation of competent barrier lipids in reconstructed hman epidermis requires the presence of vitamin C", <u>J Invest Dermatol</u> , 1997 Sep; 109(3): 348-55
	27OD	Foster, James, "Sunburn", <u>eMedicine Journal</u> , August 21, 2001, Volume 2, Number 8, downloaded June 17, 2002, pages 1-12 at http://www.emedicine.com/EMERG/topic798.htm
	28OD	ACHRE Report, "What is Ionizing Radition?", retrieved March 1, 2002, download @ http://tis.eh.doe.gov/ohre/roadmap/achre/intro_9_1.html
	29OD	Shuk-mei, H., "Drug Screening Methods for Estrogen Receptor Beta (Erb) Modulators", <u>BioScience Valuation</u> , Pharmalicensing, March 8, 2002, download retrieved March 8, 2002 @ http://atlas.pharmalicensing.com/licensing/displcopp/548
	30OD	Hyatt, B.A., et al., "The Roles of FGF's, BMP4, and SHH in Transdifferentiaion of Mouse Tracheal Epithelium in Mesenchyme-free Culture", Children's Hospital Medical Center, Cincinnati, Developmental Biology Annual Meeting, July 2001, Reprinted by Cepheid, pages 1-4
	31OD	Li, Dengju et al., "Study the Regulative Function of Extracelluar Regulated Protein Kinases and Telomerase in Apoptosis of Hepatocarcinomatous and Leukemic Cell Lines", Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, pages 1-13
	32OD	Mirasolo, S., "Actinic Dermatitis (Sunburn)", <u>Sports Medicine Articles</u> , Northeast Rehab Health Network, retrieved January 10, 2002 @ http://www.rehabnet.com/Sports/Actinic%20Dermatitis.htm pgs 1-2
	33OD	Panah S., et al., <u>Discover</u> , "Homogeneous Assays for Tyrosine Kinase and Tyrosine Phosphatase Activity Using β -Galactosidase Enzyme Fragment Complementation", Abstract.
	34OD	
	35OD	
	36OD	
	37OD	
	38OD	
	39OD	
	40OD	
	41OD	
	42OD	

EXAMINER:

DATE CONSIDERED: